BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31085770)

  • 41. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
    Mizusawa N; Uchino S; Iwata T; Tsuyuguchi M; Suzuki Y; Mizukoshi T; Yamashita Y; Sakurai A; Suzuki S; Beniko M; Tahara H; Fujisawa M; Kamata N; Fujisawa K; Yashiro T; Nagao D; Golam HM; Sano T; Noguchi S; Yoshimoto K
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):9-16. PubMed ID: 16817812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
    Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
    Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance.
    Guarnieri V; Scillitani A; Muscarella LA; Battista C; Bonfitto N; Bisceglia M; Minisola S; Mascia ML; D'Agruma L; Cole DE
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2827-32. PubMed ID: 16720667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
    Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
    N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Characteristics of Large Parathyroid Adenomas.
    Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
    World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of the 2022 WHO Classification of Parathyroid Tumors.
    Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
    Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors.
    Siu WK; Law CY; Lam CW; Mak CM; Wong GW; Ho AY; Ho KY; Loo KT; Chiu SC; Chow LT; Tong SF; Chan AY
    Fam Cancer; 2011 Dec; 10(4):695-9. PubMed ID: 21732217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
    Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism.
    Masi G; Barzon L; Iacobone M; Viel G; Porzionato A; Macchi V; De Caro R; Favia G; Palù G
    Endocr Relat Cancer; 2008 Dec; 15(4):1115-26. PubMed ID: 18755853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genotype of CDC73 germline mutation determines risk of parathyroid cancer.
    Li Y; Zhang J; Adikaram PR; Welch J; Guan B; Weinstein LS; Chen H; Simonds WF
    Endocr Relat Cancer; 2020 Sep; 27(9):483-494. PubMed ID: 32590342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A large extended family with hyperparathyroidism-jaw tumor syndrome due to deletion of the third exon of CDC73: clinical and molecular features.
    Le Collen L; Barraud S; Braconnier A; Coppin L; Zachar D; Boulagnon C; Deguelte S; Souchon PF; Spodenkiewicz M; Poirsier C; Aubert S; Odou MF; Delemer B
    Endocrine; 2021 Sep; 73(3):693-701. PubMed ID: 33999366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GCM2-Activating Mutations in Familial Isolated Hyperparathyroidism.
    Guan B; Welch JM; Sapp JC; Ling H; Li Y; Johnston JJ; Kebebew E; Biesecker LG; Simonds WF; Marx SJ; Agarwal SK
    Am J Hum Genet; 2016 Nov; 99(5):1034-1044. PubMed ID: 27745835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
    Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.
    Wasserman JD; Tomlinson GE; Druker H; Kamihara J; Kohlmann WK; Kratz CP; Nathanson KL; Pajtler KW; Parareda A; Rednam SP; States LJ; Villani A; Walsh MF; Zelley K; Schiffman JD
    Clin Cancer Res; 2017 Jul; 23(13):e123-e132. PubMed ID: 28674121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Parathyroid tumors and related disorders.
    DeLellis RA
    Mod Pathol; 2011 Apr; 24 Suppl 2():S78-93. PubMed ID: 21455204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.
    Carpten JD; Robbins CM; Villablanca A; Forsberg L; Presciuttini S; Bailey-Wilson J; Simonds WF; Gillanders EM; Kennedy AM; Chen JD; Agarwal SK; Sood R; Jones MP; Moses TY; Haven C; Petillo D; Leotlela PD; Harding B; Cameron D; Pannett AA; Höög A; Heath H; James-Newton LA; Robinson B; Zarbo RJ; Cavaco BM; Wassif W; Perrier ND; Rosen IB; Kristoffersson U; Turnpenny PD; Farnebo LO; Besser GM; Jackson CE; Morreau H; Trent JM; Thakker RV; Marx SJ; Teh BT; Larsson C; Hobbs MR
    Nat Genet; 2002 Dec; 32(4):676-80. PubMed ID: 12434154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.
    Cascón A; Huarte-Mendicoa CV; Javier Leandro-García L; Letón R; Suela J; Santana A; Costa MB; Comino-Méndez I; Landa I; Sánchez L; Rodríguez-Antona C; Cigudosa JC; Robledo M
    Genes Chromosomes Cancer; 2011 Nov; 50(11):922-9. PubMed ID: 21837707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.